CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a conference call to discuss fiscal 2023 third quarter financial results. The live webcast can be accessed via Lifecore’s website on the Investor Events & Presentations page. The webcast will be available for 30 days.
Date: Thursday, June 1, 2023
Time: 7:30 a.m. Central time (8:30 a.m. Eastern time)
Direct Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1612746&tp_key=4b15043655
To participate in the conference call via telephone, dial toll-free: 1-844-826-3033 (U.S.) or 1-412-317-5185 (International). Please call the conference telephone number 5-10 minutes prior to the start time so the operator can register your name and organization.
A replay of the call will be available through June 8, by calling toll-free: 1-844-512-2921 (U.S.) or 1-412-317-6671 (International), and entering code 10178817.
About Lifecore Biomedical
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore’s website at www.lifecore.com.
Contact Information:
Investor Relations
Jeff Sonnek
(646) 277-1263
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.41 |
Daily Change: | 0.07 1.10 |
Daily Volume: | 193,677 |
Market Cap: | US$237.180M |
April 03, 2025 January 07, 2025 January 02, 2025 December 19, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load